Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: Data from a randomised, placebo-controlled, double-blind study

Diabetes and Vascular Disease Research

Volumn 7, Issue 3, 2010, Pages 178-185

  Walcher, Thomas ^a   Walcher, Daniel ^a   Hetzel, Jürgen ^b   Mielke, Catrin ^a   Rau, Matthias ^a   Rittig, Kilian ^b   Balletshofer, Bernd ^b   Schwedhelm, Edzard ^c   Hombach, Vinzenz ^a   Böger, Rainer H ^c   Koenig, Wolfgang ^a   Marx, Nikolaus ^d  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Endothelial function; Inflammation; Thiazolidinediones

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; PLACEBO; ROSIGLITAZONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM; FLOW MEDIATED ENDOTHELIUM DEPENDENT VASODILATION; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; MALE; METABOLIC PARAMETERS; MORNING DOSAGE; NORMAL HUMAN; SINGLE DRUG DOSE; VASCULARIZATION;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; PLACEBO EFFECT; THIAZOLIDINEDIONES; TIME FACTORS; VASODILATION; YOUNG ADULT;

EID: 79551715853     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164110367812     Document Type: Article

References (40)

1. Behrendt, D., Ganz, P. (2002) Endothelial function. From vascular biology to clinical applications. Am J Cardiol 90 (10C). 40 L-8L. (Pubitemid 35379905)
2. De Caterina, R., Libby P., Peng H.B., et al. (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 96 (1). 60-8.
3. Ganz, P., Vita, J.A. (2003) Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 108 (17). 2049-53. (Pubitemid 37337576)
4. Kinlay, S., Libby. P., Ganz, P. (2001) Endothelial function and coronary artery disease. Curr Opin Lipidol 12 (4). 383-9. (Pubitemid 32675498)
5. Gimbrone, M.A., Jr., Cybulsky, M.I., Kume, N., Collins, T., Resnick, N. (1995) Vascular endothelium. An integrator of pathophysiological stimuli in atherogenesis. Ann N Y Acad Sci 748: 122-31 ; discussion 31-2.
6. Dupuis, J., Tardif, J.C., Cernacek, P., Theroux, P. (1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99 (25). 3227-33. (Pubitemid 29293431)
7. Laufs, U., Wassmann, S., Hilgers, S., Ribaudo, N., Bohm, M., Nickenig, G. (2001) Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 88 (11). 1306-7. (Pubitemid 33132103)
8. Murakami, T., Mizuno, S., Ohsato, K., et al. (1999) Effects of troglitazone on frequency of coronary vasospasticinduced angina pectoris in patients with diabetes mellitus. Am J Cardiol 84 (1). 92-4. (Pubitemid 29307648)
9. Pistrosch, F., Passauer, J., Fischer, S., Fuecker, K., Hanefeld, M., Gross, P. (2004) In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27: 484-90. (Pubitemid 38174076)
10. Caballero, A.E., Saouaf, R., Lim, S.C., et al. (2003) The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 52 (2). 173-80. (Pubitemid 36388839)
11. Wang, T.D., Chen, W.J., Lin, J.W., Chen, M.F., Lee, Y.T. (2004) Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 93 (3). 362-5.
12. Hetzel, J., Balletshofer, B., Rittig, K., et al. (2005) Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25: 1804-9. (Pubitemid 41243446)
13. Calnek, D.S., Mazzella, L., Roser, S., Roman, J., Hart, C.M. (2003) Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23 (1). 52-7. (Pubitemid 36091625)
14. Celermajer, D.S., Sorensen, K.E., Gooch, V.M., et al. (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (8828). 1111-5.
15. Balletshofer, B.M., Goebbel, S., Rittig, K., et al. (2001) Einfluss der Untersuchererfahrung auf intra- und interindividuelle Variabilitat bei der Erfassung der peripheren Endothelfunktion mittels hochauflosendem Ultraschall. Ultraschall Med 22 (5). 231-5. (Pubitemid 33078024)
16. Joannides, R., Haefeli, W.E., Linder, L., et al. (1995) Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91 (5). 1314-9.
17. Corretti, M.C., Anderson, T.J., Benjamin, E.J., et al. (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2). 257-65. (Pubitemid 34084631)
18. Schwedhelm, E., Maas, R., Tan-Andresen, J., Schulze, F., Riederer, U., Boger, R.H. (2007) High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 851 (1-2). 211-9. (Pubitemid 46720141)
19. Koenig, W., Rothenbacher, D., Hoffmeister, A., Griesshammer, M., Brenner, H. (2001) Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol 21 (10). 1701-5. (Pubitemid 34215594)
20. Dandona (2001) Diabetologia 44 (Suppl 1). A36
21. Kanda, T., Brown, J.D., Orasanu, G., et al. (2009) PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice. J Clin Invest 119 (1). 110-24.
22. Cominacini, L., Young, M.M., Capriati, A., et al. (1997) Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia 40 (10). 1211-8. (Pubitemid 27421894)
23. Raskin, P., Rappaport, E.B., Cole, S.T., Yan, Y., Patwardhan, R., Freed, M.I. (2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43 (3). 278-84. (Pubitemid 30163470)
24. Hammarstedt, A., Andersson, C.X., Rotter Sopasakis, V., Smith, U. (2005) The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot Essent Fatty Acids 73 (1). 65-75. (Pubitemid 40826930)
25. Riera-Guardia, N., Rothenbacher, D. (2008) The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab 10 (5). 367-75. (Pubitemid 351524284)
26. Balletshofer, B.M., Rittig, K., Enderle, M.D., et al. (2000) Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101 (15). 1780-4. (Pubitemid 30213098)
27. Otto, M.E., Svatikova, A., Barretto, R.B., et al. (2004) Early morning attenuation of endothelial function in healthy humans. Circulation 109 (21). 2507-10. (Pubitemid 38720548)
28. Bevilacqua, M.P., Stengelin, S., Gimbrone, M.A., Jr., Seed, B. (1989) Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243 (4895). 1160-5. (Pubitemid 19081142)
29. Boger, R.H. (2006) Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 38 (2). 126-36.
30. Stuhlinger, M.C., Abbasi, F., Chu, J.W., et al. (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (11). 1420-6. (Pubitemid 34250505)
31. Wang, T.D., Chen, W.J., Cheng, W.C., Lin, J.W., Chen, M.F., Lee, Y.T. (2006) Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 98 (8). 1057-62.
32. Chaudhry, J., Ghosh, N.N., Roy, K., Chandra, R. (2007) Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxaninduced diabetic rats. Life Sci 80 (12). 1135-42. (Pubitemid 46241223)
33. Sidhu, J.S., Cowan, D., Kaski, J.C. (2004) Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 64 (2). 151-6. (Pubitemid 38902860)
34. Hanefeld, M., Marx, N., Pfutzner, A., et al. (2007) Antiinflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 49 (3). 290-7. (Pubitemid 46110954)
35. Pfutzner, A., Marx, N., Lubben, G., et al. (2005) Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (12). 1925-31. (Pubitemid 40814110)
36. Sidhu, J.S., Kaposzta, Z., Markus, H.S., Kaski, J.C. (2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24 (5). 930-4. (Pubitemid 38620874)
37. Sidhu, J.S., Cowan, D., Tooze, J.A., Kaski, J.C. (2004) Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 147 (6). e25.
38. Nissen, S.E., Wolski, K. (2007) Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 356 (24). 2457-71. (Pubitemid 46919772)
39. Singh, S., Loke, Y.K., Furberg, C.D. (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Jama 298 (10). 1189-95. (Pubitemid 47403105)
40. Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. (2007) Rosiglitazone Evaluated for Cardiovascular Outcomes - An Interim Analysis. N Engl J Med 357 (1). 28-38. (Pubitemid 47026732)